Ipratropium bromide/salbutamol: Difference between revisions
Content deleted Content added
therapeutic applications — asthma |
|||
| Line 45: | Line 45: | ||
<!-- History and culture --> |
<!-- History and culture --> |
||
The combination was approved for medical use in the United States in 1996.<ref name=Pro2019>{{cite web |title=Ipratropium and Albuterol - FDA prescribing information, side effects and uses |url=https://www.drugs.com/pro/ipratropium-and-albuterol.html |website=Drugs.com |access-date=18 April 2019 |language=en}}</ref> It is available as a [[generic medication]].<ref name=BNF76>{{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=247|edition=76}}</ref> In 2021, it was the 151st most commonly prescribed medication in the United States, with more than 3{{nbsp}}million prescriptions.<ref>{{cite web | title=The Top 300 of 2021 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=14 January 2024 | archive-date=15 January 2024 | archive-url=https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Albuterol; Ipratropium - Drug Usage Statistics | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/AlbuterolIpratropium | access-date = 14 January 2024 }}</ref> |
The combination was approved for medical use in the United States in 1996.<ref name=Pro2019>{{cite web |title=Ipratropium and Albuterol - FDA prescribing information, side effects and uses |url=https://www.drugs.com/pro/ipratropium-and-albuterol.html |website=Drugs.com |access-date=18 April 2019 |language=en}}</ref> It is available as a [[generic medication]].<ref name=BNF76>{{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=247|edition=76}}</ref> In 2021, it was the 151st most commonly prescribed medication in the United States, with more than 3{{nbsp}}million prescriptions.<ref>{{cite web | title=The Top 300 of 2021 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=14 January 2024 | archive-date=15 January 2024 | archive-url=https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Albuterol; Ipratropium - Drug Usage Statistics | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/AlbuterolIpratropium | access-date = 14 January 2024 }}</ref> |
||
==Medical uses== |
|||
Ipratropium bromide/salbutamol can be used for the treatment of asthma.<ref name="Donohue et al., 2016">{{cite journal |last1=Donohue |first1=JF |last2=Wise |first2=R |last3=Busse |first3=WW |last4=Garfinkel |first4=S |last5=Zubek |first5=VB |last6=Ghafouri |first6=M |last7=Manuel |first7=RC |last8=Schlenker-Herceg |first8=R |last9=Bleecker |first9=ER |title=Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. |journal=BMC pulmonary medicine |date=30 April 2016 |volume=16 |issue=1 |pages=65 |doi=10.1186/s12890-016-0223-3 |pmid=27130202}}</ref> |
|||
==Society and culture== |
==Society and culture== |
||
Revision as of 20:42, 25 March 2024
| Combination of | |
|---|---|
| Ipratropium bromide | Muscarinic antagonist |
| Salbutamol | Short-acting β2-adrenergic agonist |
| Clinical data | |
| Trade names | Combivent, Duoneb, Breva, others |
| AHFS/Drugs.com | Professional Drug Facts |
| MedlinePlus | a601063 |
| License data | |
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| (verify) | |
Ipratropium bromide/salbutamol, sold under the brand name Combivent among others, is a combination medication used to treat chronic obstructive pulmonary disease (COPD).[1][4][5] It contains ipratropium (an anticholinergic) and salbutamol (albuterol, a β2-adrenergic agonist).[1]
Common side effects include sore throat, muscle cramps, and nausea.[1] Other side effects may include bronchospasm, allergic reactions, and upper respiratory tract infections.[1] Safety in pregnancy is unclear.[6][1]
The combination was approved for medical use in the United States in 1996.[7] It is available as a generic medication.[4] In 2021, it was the 151st most commonly prescribed medication in the United States, with more than 3 million prescriptions.[8][9]
Medical uses
Ipratropium bromide/salbutamol can be used for the treatment of asthma.[10]
Society and culture
Since Combivent contains a chlorofluorocarbon-based propellant, its use was discontinued in 2013 in the United States and other countries. This is because chlorofluorocarbons are attributed to depletion of the ozone layer.[11]
References
- ^ a b c d e f "Combivent Respimat- ipratropium bromide and albuterol spray, metered". DailyMed. 24 January 2022. Retrieved 30 October 2022.
- ^ "DuoNeb". DailyMed. Retrieved 30 October 2022.
- ^ "Combivent (ipratropium bromide and albuterol sulfate) Inhalation Aerosol". DailyMed. Retrieved 30 October 2022.
- ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 247. ISBN 9780857113382.
- ^ Gordon J, Panos RJ (March 2010). "Inhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary disease". Expert Opinion on Drug Metabolism & Toxicology. 6 (3): 381–92. doi:10.1517/17425251003649549. PMID 20163324. S2CID 31806856.
- ^ "Albuterol / ipratropium Use During Pregnancy". Drugs.com. Retrieved 19 April 2019.
- ^ "Ipratropium and Albuterol - FDA prescribing information, side effects and uses". Drugs.com. Retrieved 18 April 2019.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Albuterol; Ipratropium - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
- ^ Donohue JF, Wise R, Busse WW, Garfinkel S, Zubek VB, Ghafouri M, et al. (30 April 2016). "Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial". BMC pulmonary medicine. 16 (1): 65. doi:10.1186/s12890-016-0223-3. PMID 27130202.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ "Phase Out of Combivent Inhalation Aerosol - Questions and Answers". FDA. 3 November 2018.
